- Theratechnologies (TH) has initiated a basket trial for its study in advanced resistant tumors
- The first-in-human study is evaluating TH1902 for the treatment of solid tumors tied to sortilin-expressing cancers
- TH1902 allows greater quantities of cancer drug docetaxel to enter infected cells compared to administering the drug on its own
- Based on pre-clinical results, the company is confident in its drug candidate’s effectiveness
- Theratechnologies is a biopharmaceutical company focused on oncology, HIV and Non-Alcoholic Steatohepatitis
- Theratechnologies (TH) is up by 2.65 per cent trading at $3.10 per share
Theratechnologies (TH) has initiated a basket trial for its study in advanced resistant tumors.
A basket trial is a clinical trial that tests how well a new drug works in patients with different cancers that share the same mutation or biomarker, which the drug will target.
The first-in-human study is evaluating TH1902 for the treatment of solid tumors tied to sortilin-expressing cancers.
TH1902 enables the potential to accumulate 7.5 to 10 times more docetaxel, a well-established cancer drug, in infected cells, compared to administering the drug on its own.
Cancers to be studied include breast, ovarian, endometrial, melanoma, thyroid, small cell lung and prostate.
“We firmly believe that the unique mechanism of entry of TH1902 in cancer cells is a key advantage to improve the therapeutic window of docetaxel. Based on the pre-clinical results obtained so far, we are optimistic in the development of a first-in-class and promising treatment for patients with sortilin-positive solid tumors,” stated Dr. Christian Marsolais, Senior Vice President and Chief Medical Officer at Theratechnologies.
Theratechnologies is a biopharmaceutical company focused on oncology, HIV and Non-Alcoholic Steatohepatitis.
Theratechnologies (TH) is up by 2.65 per cent trading at $3.10 per share as of 9:39 am EST.